FIELD: medicine.
SUBSTANCE: invention concerns medicine area, in particular ophthalmology, namely, -ophthalmo-oncology. The method includes performance of the immunohistochemical analysis of an expression of proteins S-100 and HMB-45 in tumoral cells with simultaneous calculation of quantity of S-100-positive cells in sight. Verify uveal melanoma at positive reaction S-100 and HMB-45 with prediction of high probability of tumour innidiation at presence in it less than 50 S-100-positive cells.
EFFECT: possibility of uveal melanoma verification and prediction of probability of its innidiation.
1 tbl, 1 dwg, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF SIMULTANEOUS VERIFICATION OF UVEAL MELANOMA COURSE FORECAST | 2006 |
|
RU2327420C1 |
| METHOD FOR PREDICTION OF SURVIVAL RATE AFTER ENUCLEATION WITH UVEAL MELANOMA DEVELOPED TO EQUATOR | 2024 |
|
RU2822319C1 |
| METHOD FOR DETERMINING TIME OF FIRST METASTASIS AFTER ENUCLEATION IN UVEAL MELANOMA | 2024 |
|
RU2827578C1 |
| METHOD OF PREDICTION OF CLINICAL COURSE OF UVEA MELANOMA BASED ON APOPTHOSIS MARKER Bax | 2002 |
|
RU2208790C1 |
| METHOD FOR PREDICTING METASTASES OF UVEAL MELANOMA BASED UPON APOPTOSIS MARKERS BAX AND BCL-2 | 2003 |
|
RU2242766C1 |
| METHOD FOR PREDICTING UVEAL MELANOMA METASTASIS SPREAD WITH APOPTOSIS MARKERS BAX AND BCL-2 | 2003 |
|
RU2244934C2 |
| METHOD FOR PREDICTING UVEAL MELANOMA METASTASIS FORMATION ON THE BASIS OF BAX AND KI-67 MARKERS | 2003 |
|
RU2240560C1 |
| METHOD PREDICTING CLINICAL COURSE OF UVEA MELANOMA BASED ON APOPTHOSIS MARKER p53 | 2002 |
|
RU2208789C1 |
| METHOD FOR PREDICTING CLINICAL FLOW OF UVEAL MELANOMA | 2001 |
|
RU2193200C1 |
| METHOD FOR PREDICTING CLINICAL COURSE OF UVEAL MELANOMA DEVELOPMENT | 2001 |
|
RU2197731C2 |
